Cetera Investment Advisers Has $2.09 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Cetera Investment Advisers increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,280 shares of the life sciences company’s stock after purchasing an additional 3,173 shares during the quarter. Cetera Investment Advisers’ holdings in Illumina were worth $2,085,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ILMN. Freedom Investment Management Inc. grew its holdings in Illumina by 3.7% during the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company’s stock worth $382,000 after acquiring an additional 101 shares during the last quarter. Probity Advisors Inc. increased its position in Illumina by 12.2% in the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company’s stock valued at $274,000 after acquiring an additional 224 shares in the last quarter. Xponance Inc. increased its position in Illumina by 1.0% in the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company’s stock valued at $2,123,000 after acquiring an additional 264 shares in the last quarter. Rakuten Securities Inc. increased its position in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 270 shares in the last quarter. Finally, Golden State Wealth Management LLC increased its position in Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 292 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $95.50 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The firm’s 50 day moving average price is $94.89 and its two-hundred day moving average price is $91.78. The firm has a market cap of $14.68 billion, a P/E ratio of 12.09, a PEG ratio of 2.12 and a beta of 1.37.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the company earned $0.36 earnings per share. The firm’s revenue was down 4.8% compared to the same quarter last year. On average, analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity

In other Illumina news, CFO Ankur Dhingra acquired 6,100 shares of the stock in a transaction dated Monday, May 12th. The shares were bought at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the acquisition, the chief financial officer directly owned 24,906 shares of the company’s stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ILMN. JPMorgan Chase & Co. lowered their price objective on shares of Illumina from $120.00 to $85.00 and set a “neutral” rating for the company in a research report on Friday, May 9th. Evercore ISI lifted their price objective on shares of Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Royal Bank Of Canada lifted their price objective on shares of Illumina from $118.00 to $126.00 and gave the stock an “outperform” rating in a research note on Friday, August 1st. Scotiabank lowered shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Finally, Robert W. Baird lifted their price objective on shares of Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a research note on Monday, July 28th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $127.74.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.